Capital Management Corp VA Buys 9,815 Shares of Bristol Myers Squibb Company $BMY

Capital Management Corp VA lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 9.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 111,670 shares of the biopharmaceutical company’s stock after purchasing an additional 9,815 shares during the quarter. Capital Management Corp VA’s holdings in Bristol Myers Squibb were worth $5,036,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in BMY. Trifecta Capital Advisors LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth $25,000. Harbor Capital Advisors Inc. raised its position in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares in the last quarter. REAP Financial Group LLC boosted its stake in Bristol Myers Squibb by 202.8% during the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 428 shares during the period. Finally, DHJJ Financial Advisors Ltd. grew its position in Bristol Myers Squibb by 51.9% during the second quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 267 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY opened at $55.03 on Friday. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The stock’s 50 day simple moving average is $53.41 and its 200 day simple moving average is $48.66. The firm has a market cap of $112.02 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. As a group, analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.6%. The ex-dividend date of this dividend is Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is currently 85.14%.

Wall Street Analyst Weigh In

BMY has been the subject of a number of research analyst reports. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. UBS Group raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 3rd. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Finally, Citigroup reiterated a “neutral” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $57.43.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.